Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Delfi Diagnostics Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The current prosecution landscape for the company involves 1 distinct examiner and 1 distinct art unit. This focus suggests that the company is currently prioritizing 1 specific technological advancement rather than managing a multi-faceted portfolio. The concentration in 1 distinct art unit implies a specific technical classification for the company's current Biotechnology & Pharmaceuticals research.
GRAY, JESSICA is the busiest examiner for the company, with 1 pending office action under review. Because there is 1 pending office action in total, the examiner's individual approach will be the primary factor in the company's immediate patenting success. The presence of 1 distinct examiner indicates that the subject matter has not yet branched into secondary technical classifications. This requires a prosecution strategy that is responsive to the specific feedback of GRAY, JESSICA.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GRAY, JESSICA | 1 | 0.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18286081 | METHOD OF DETECTING CANCER USING GENOME-WIDE CFDNA FRAGMENTATION PROFILES | GRAY, JESSICA | — |
| Art Unit | Apps |
|---|---|
| 1682 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18286081 | METHOD OF DETECTING CANCER USING GENOME-WIDE CFDNA FRAGMENTATION PROFILES | GRAY, JESSICA | 1682 | §103§112DP | Final Rejection | — | Pending | Oct 06, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial